The aim of this study was to investigate the relationship between HBV DNA levels at baseline and on-treatment and the virological response at 96 weeks after adefovir add-on therapy in chronic hepatitis B (CHB) patients with lamivudine resistance.
Methods
Lamivudine and adefovir combination therapy was administered to 122 CHB patients for >24 months.
Results
Virological response (HBV DNA negativity) was achieved in 53 (43.3%) and 62 patients (50.8%) at 48 and 96 weeks, respectively. The receiver operating characteristic curve analysis showed that the HBV DNA level at week 24 had a greater power (area under the receiver operating characteristic curve 0.978; 95% CI 0.949, 1.000; P<0.001) to predict the virological response at week 96 of treatment than did the pre-treatment HBV DNA level (area under the receiver operating characteristic curve 0.771; 95% CI 0.640, 0.902; P<0.001). The best cutoff value for the HBV DNA level, at week 24, for the prediction of the virological response at week 96 was 200 IU/ ml (3 log10 copies/ml), with a sensitivity and specificity of 90.3% and 95.0%, respectively. Using this time frame and cutoff value, 56 (90.3%) out of 62 patients that had a virological response at 96 weeks had <200 IU/ml HBV DNA at 24 weeks.
Conclusions
Although the HBV DNA level at baseline is often used to predict the antiviral potency of lamivudine and adefovir combination treatment in CHB patients with lamivudine resistance, the results of this study suggest that the HBV DNA level at 24 weeks is a better marker for the virological response.
References
1.
ChenC.J., YangH.I., SuJ.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006; 295: 65–73.
2.
IloejeU.H., YangH.I., SuJ.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology2006; 130: 678–686.
3.
LiawY.F., LeungN.W., ChangT.T.Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology2000; 119: 172–180.
4.
LauD.T., KhokharM.F., DooE.Long-term therapy of chronic hepatitis B with lamivudine. Hepatology2000; 32: 828–834.
5.
LokA.S., LaiC.L., LeungN.Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology2003; 125: 1714–1722.
6.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med2003; 348: 800–807.
7.
MarcellinP., ChangT.T., LimS.G.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med2003; 348: 808–816.
8.
PetersM.G., Hann HwH., MartinP.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology2004; 126: 91–101.
9.
PerrilloR., HannH.W., MutimerD.Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology2004; 126: 81–90.
10.
FungJ., LaiC.L., YuenJ.C.Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther2007; 12: 41–46.
11.
RaptiI., DimouE., MitsoulaP., HadziyannisS.J.Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology2007; 45: 307–313.
12.
ChenC.H., WangJ.H., LeeC.M.Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther2006; 11: 771–778.
13.
FungS.K., ChaeH.B., FontanaR.J.Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol2006; 44: 283–290.
14.
ChanH.L., WongV.W., TseC.H.Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther2007; 25: 891–898.
15.
YatsujiH., SuzukiF., SezakiH.Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. J Hepatol2008; 48: 923–931.
16.
HosakaT., SuzukiF., SuzukiY.Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol2007; 42: 368–374.
17.
LamperticoP., ViganoM., ManentiE.Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology2005; 42: 1414–1419.
18.
ButiM., ElefsiniotisI., JardiR.Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol2007; 47: 366–372.
19.
YuenM.F., FongD.Y., WongD.K.Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology2007; 46: 1695–1703.
20.
LaiC.L., LeungN., TeoE.K.A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology2005; 129: 528–536.
21.
ChanH.L., HeathcoteE.J., MarcellinP.Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med2007; 147: 745–754.
22.
GallegoA., SheldonJ., Garcia-SamaniegoJ.Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat2008; 15: 392–398.
23.
ShinJ.W., ParkN.H., JungS.W.Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther2009; 14: 181–186.
24.
KimM.C., JungS.W., ShinJ.W., ParkN.H.The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. Dig Dis Sci2011; 56: 1215–1221.
25.
LamperticoP., ViganoM., ManentiE.Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology2007; 133: 1445–1451.
26.
VassiliadisT., NikolaidisN., GioulemeO.Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther2005; 21: 531–537.
27.
KurashigeN., HiramatsuN., OhkawaK.Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol2009; 44: 601–607.
28.
BergT., MarcellinP., ZoulimF.Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology2010; 139: 1207–1217.
29.
van BömmelF., de ManR.A., WedemeyerH.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology2010; 51: 73–80.
30.
YuenM.F., SablonE., HuiC.K.Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology2001; 34: 785–791.
31.
LokA.S., McMahonB.J.Chronic hepatitis B. Hepatology2007; 45: 507–539.
32.
KeeffeE.B., DieterichD.T., HanS.H.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol2006; 4: 936–962.
33.
KimH., JeeY.M., SongB.C.Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology2007; 50: 52–57.
